BR0010783A - Novos compostos, seu uso e preparação - Google Patents
Novos compostos, seu uso e preparaçãoInfo
- Publication number
- BR0010783A BR0010783A BR0010783-2A BR0010783A BR0010783A BR 0010783 A BR0010783 A BR 0010783A BR 0010783 A BR0010783 A BR 0010783A BR 0010783 A BR0010783 A BR 0010783A
- Authority
- BR
- Brazil
- Prior art keywords
- ring
- saturated
- disorders
- substituted
- ring members
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- -1 (i) -O- Chemical class 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 125000004474 heteroalkylene group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical class N* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Chemical group 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"NOVOS COMPOSTOS, SEU USO E PREPARAçãO". A invenção refere-se a compostos de fórmula geral (I): onde: Ar é aril ou heteroaril opcionalmente substituído; A é (i) -O-, -S-, -SO~ 2~-, -NH-, (ii) um átomo de nitrogênio C~ 1-4~-alquil-substituído ou C~ 1-6~-acil-substituído ou (iii) uma cadeia C~ 1-8~-alquileno ou uma cadeia heteroalquileno possuindo de 2 até 8 átomos de cadeia, que opcionalmente contem ao menos uma insaturação, e que pode ser substituída e/ou conter uma ponte que forma um anel saturado ou parcialmente ou completamente insaturado contendo 3-8 membros; B é -C(R~ 4~) (R~ 5~)-, -OC(R~ 4~) (R~ 5~)-, -N(R~ 6~)C(R~ 4~) (R~ 5~)-, -N(R~ 6~)-O-, -S- ou -SO~ 2~-; R é C~ 3-8~-cicloalquil, aril ou heteroaril opcionalmente substituídos; R~ 1~ é (i) um anel azacíclico ou aminoazacíclico saturado ou insaturado, ou um anel diazacíclico ou aminodiazacíclico saturado, possuindo de 4 até 7 membros de anel, ou um anel aminoazabicíclico, azabicíclico ou diazabicíclico saturado possuindo de 7 até 10 membros de anel, cada anel sendo opcionalmente substituído em uma ou mais posições, ou (ii) um grupo - [C (R~ 4~) (R~ 5~)] xN (R~ 2a~) (R~ 3a~); R~ 2a~, R~ 3a~, R~ 4~, R~ 5~, e x são como definidos nas reivindicações, e n é 0 ou 1; e sais, hidratos e formas pró-droga dos mesmos farmaceuticamente aceitáveis. Os compostos podem ser preparados métodos per se convencionais e podem ser utilizados para o tratamento de seres humanos e animais que sofrem de distúrbios relacionados à serotonina, especialmente obesidade, distúrbios da memória, esquizofrenia, distúrbios do humor, ansiedade, dor, disfunções sexuais, e distúrbios urinários. A invenção também se refere a tais utilizações bem como a composições farmacêuticas compreendendo um composto de fórmula (I).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9901884A SE9901884D0 (sv) | 1999-05-21 | 1999-05-21 | Novel compounds their use and preparation |
| US13752799P | 1999-06-03 | 1999-06-03 | |
| PCT/SE2000/001017 WO2000076984A2 (en) | 1999-05-21 | 2000-05-19 | Novel compounds, their use and preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0010783A true BR0010783A (pt) | 2002-04-09 |
Family
ID=26663577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0010783-2A BR0010783A (pt) | 1999-05-21 | 2000-05-19 | Novos compostos, seu uso e preparação |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1178973B1 (pt) |
| KR (1) | KR100722090B1 (pt) |
| CN (1) | CN1242995C (pt) |
| AT (1) | ATE313535T1 (pt) |
| AU (1) | AU777276C (pt) |
| BR (1) | BR0010783A (pt) |
| CA (1) | CA2374898C (pt) |
| DE (1) | DE60024986T2 (pt) |
| DK (1) | DK1178973T3 (pt) |
| EA (1) | EA005820B1 (pt) |
| ES (1) | ES2252004T3 (pt) |
| HK (1) | HK1048311B (pt) |
| IL (2) | IL146582A0 (pt) |
| MX (1) | MXPA01011905A (pt) |
| NO (1) | NO322220B1 (pt) |
| NZ (1) | NZ515786A (pt) |
| WO (1) | WO2000076984A2 (pt) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0004244D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
| SE0004245D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
| JP4204315B2 (ja) | 2000-11-20 | 2009-01-07 | ビオヴィトルム・アクチボラゲット（プブリクト） | セロトニン５−ｈｔ２レセプターのアンタゴニストとしてのピペラジニルピラジン化合物 |
| GB0109103D0 (en) * | 2001-04-11 | 2001-05-30 | Pfizer Ltd | Novel compounds |
| US20030207857A1 (en) | 2001-04-11 | 2003-11-06 | Adam Mavis D. | Phenyl heterocyclyl ethers |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| AU2002352878B2 (en) * | 2001-11-27 | 2007-11-22 | Merck Sharp & Dohme Corp. | 2-Aminoquinoline compounds |
| US6872826B2 (en) * | 2002-03-29 | 2005-03-29 | Schering Corporation | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines |
| WO2003105850A1 (en) * | 2002-06-18 | 2003-12-24 | Abbott Laboratories | 2-aminoquinolines as melanin concentrating hormone receptor antagonists |
| US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
| WO2004000829A1 (en) * | 2002-06-19 | 2003-12-31 | Biovitrum Ab | Novel process |
| US7226925B2 (en) | 2002-06-19 | 2007-06-05 | Biovitrum Ab | Compounds, their use and preparation |
| US7129354B2 (en) | 2002-06-19 | 2006-10-31 | Biovitrum Ab | Process for the preparation of stable acid addition salt of 2,3-disubstituted pyrazine compounds |
| BR0311970A (pt) | 2002-06-19 | 2005-03-29 | Biovitrum Ab | Novos compostos, seu uso e preparação |
| SE0202287D0 (sv) * | 2002-07-19 | 2002-07-19 | Biovitrum Ab | New compounds |
| DK1534391T3 (da) | 2002-07-19 | 2007-06-11 | Biovitrum Ab | Nye piperazinyl-pyrazinonderivater til behandling af 5-HT2A-recptor-relaterede forstyrrelser |
| CA2517291C (en) | 2003-03-19 | 2012-05-08 | Exelixis, Inc. | Ortho-substituted aryl and heteroaryl tie-2 modulators and methods of use |
| CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
| WO2005037199A2 (en) | 2003-10-10 | 2005-04-28 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| JP2007531753A (ja) | 2004-03-31 | 2007-11-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 非イミダゾール系複素環式化合物 |
| JP5173190B2 (ja) | 2004-08-25 | 2013-03-27 | 武田薬品工業株式会社 | 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法 |
| GT200500317A (es) | 2004-11-05 | 2006-10-27 | Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos | |
| EA012245B1 (ru) | 2004-11-29 | 2009-08-28 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эд-Эл-Си | Терапевтические пиразоло[3,4-b]пиридины и индазолы |
| NZ560917A (en) | 2005-03-31 | 2011-01-28 | Pfizer Prod Inc | Cyclopentapyridine and tetrahydroquinoline derivatives |
| AR054849A1 (es) | 2005-07-26 | 2007-07-18 | Wyeth Corp | Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas |
| WO2007112073A2 (en) * | 2006-03-24 | 2007-10-04 | Wyeth | Methods for modulating bladder function |
| EP1998781A2 (en) * | 2006-03-24 | 2008-12-10 | Wyeth a Corporation of the State of Delaware | Treatment of pain |
| JP5528699B2 (ja) | 2006-05-16 | 2014-06-25 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
| MX339668B (es) | 2006-05-30 | 2016-06-02 | Janssen Pharmaceutica N V * | Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina. |
| EA019104B1 (ru) | 2007-09-21 | 2014-01-30 | Эррей Биофарма Инк. | Активаторы глюкокиназы |
| JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
| CN105712977B (zh) | 2007-11-20 | 2021-06-29 | 詹森药业有限公司 | 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物 |
| BR112012010220A2 (pt) * | 2009-10-30 | 2021-02-23 | Janssen Pharmaceutical N.V. | piridinas fenóxi-substituídas como modulares do receptor opioide |
| AU2010313392B2 (en) | 2009-10-30 | 2015-07-09 | Janssen Pharmaceutica Nv | Pyrazines as delta opioid receptor modulators |
| BR112012010253A8 (pt) | 2009-10-30 | 2016-10-04 | Janssen Pharmaceutica Nv | compostos de pirimidina como moduladores do receptor delta opioide |
| WO2011071136A1 (ja) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| BR112013007651A2 (pt) | 2010-09-28 | 2019-09-24 | Bristol-Myers Squibb Company | análogos de piperazina com grupos heteroarila substituídos como antivirais de influenza de amplo espectro |
| ES2649116T3 (es) | 2011-12-22 | 2018-01-10 | Kancera Ab | Bisarilsulfonamidas útiles en el tratamiento de inflamación y cáncer |
| GB201312131D0 (en) * | 2013-07-05 | 2013-08-21 | Proximagen Ltd | Drug combination and its use in therapy |
| GB201312129D0 (en) * | 2013-07-05 | 2013-08-21 | Proximagen Ltd | Drug combination and its use in therapy |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| CN105348204B (zh) * | 2015-11-18 | 2018-09-14 | 乳源瑶族自治县大众药品贸易有限公司 | 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途 |
| CN105461635B (zh) * | 2015-11-18 | 2018-06-08 | 乳源瑶族自治县大众药品贸易有限公司 | 苯基哌嗪衍生物及其使用方法和用途 |
| CN108409729B (zh) * | 2017-02-09 | 2020-11-24 | 广东东阳光药业有限公司 | 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途 |
| WO2019131902A1 (ja) | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
| CN109111383B (zh) * | 2018-09-14 | 2020-11-24 | 广东东阳光药业有限公司 | 2-取代的二苯硫醚衍生物及其用途 |
| JP7337174B2 (ja) | 2018-09-18 | 2023-09-01 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体 |
| CN114394887A (zh) * | 2022-01-28 | 2022-04-26 | 江苏锐鸣材料科技有限公司 | 一种苯基氧乙醇化合物及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI193974A7 (pt) * | 1973-07-13 | 1975-01-14 | Merck & Co Inc | |
| GB9313913D0 (en) * | 1993-07-06 | 1993-08-18 | Smithkline Beecham Plc | Novel compounds |
| GB9420999D0 (en) * | 1994-10-18 | 1994-12-07 | Smithkline Beecham Plc | Novel compounds |
| AU4037699A (en) * | 1998-05-08 | 1999-11-29 | Akzo Nobel N.V. | Novel aryl-hydro naphthalenal kanamines |
-
2000
- 2000-05-19 CA CA002374898A patent/CA2374898C/en not_active Expired - Fee Related
- 2000-05-19 EA EA200101223A patent/EA005820B1/ru not_active IP Right Cessation
- 2000-05-19 DK DK00931877T patent/DK1178973T3/da active
- 2000-05-19 EP EP00931877A patent/EP1178973B1/en not_active Expired - Lifetime
- 2000-05-19 AU AU49690/00A patent/AU777276C/en not_active Ceased
- 2000-05-19 ES ES00931877T patent/ES2252004T3/es not_active Expired - Lifetime
- 2000-05-19 BR BR0010783-2A patent/BR0010783A/pt not_active Application Discontinuation
- 2000-05-19 IL IL14658200A patent/IL146582A0/xx unknown
- 2000-05-19 NZ NZ515786A patent/NZ515786A/en not_active IP Right Cessation
- 2000-05-19 CN CNB008102449A patent/CN1242995C/zh not_active Expired - Fee Related
- 2000-05-19 HK HK03100371.6A patent/HK1048311B/zh not_active IP Right Cessation
- 2000-05-19 AT AT00931877T patent/ATE313535T1/de active
- 2000-05-19 MX MXPA01011905A patent/MXPA01011905A/es active IP Right Grant
- 2000-05-19 DE DE60024986T patent/DE60024986T2/de not_active Expired - Lifetime
- 2000-05-19 KR KR1020017014888A patent/KR100722090B1/ko not_active Expired - Fee Related
- 2000-05-19 WO PCT/SE2000/001017 patent/WO2000076984A2/en not_active Ceased
-
2001
- 2001-11-19 IL IL146582A patent/IL146582A/en not_active IP Right Cessation
- 2001-11-21 NO NO20015686A patent/NO322220B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE313535T1 (de) | 2006-01-15 |
| IL146582A0 (en) | 2002-07-25 |
| EA200101223A1 (ru) | 2002-06-27 |
| KR100722090B1 (ko) | 2007-05-25 |
| KR20020016795A (ko) | 2002-03-06 |
| EP1178973B1 (en) | 2005-12-21 |
| NO322220B1 (no) | 2006-08-28 |
| ES2252004T3 (es) | 2006-05-16 |
| CN1360583A (zh) | 2002-07-24 |
| AU777276B2 (en) | 2004-10-07 |
| EA005820B1 (ru) | 2005-06-30 |
| AU4969000A (en) | 2001-01-02 |
| DK1178973T3 (da) | 2006-05-08 |
| AU777276C (en) | 2005-07-07 |
| NO20015686L (no) | 2002-01-15 |
| CA2374898A1 (en) | 2000-12-21 |
| CN1242995C (zh) | 2006-02-22 |
| CA2374898C (en) | 2009-12-08 |
| NO20015686D0 (no) | 2001-11-21 |
| WO2000076984A2 (en) | 2000-12-21 |
| DE60024986D1 (de) | 2006-01-26 |
| HK1048311A1 (en) | 2003-03-28 |
| WO2000076984A3 (en) | 2001-02-08 |
| DE60024986T2 (de) | 2006-07-27 |
| WO2000076984A8 (en) | 2001-07-19 |
| NZ515786A (en) | 2004-01-30 |
| HK1048311B (zh) | 2006-08-11 |
| EP1178973A2 (en) | 2002-02-13 |
| IL146582A (en) | 2010-04-29 |
| MXPA01011905A (es) | 2004-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1178973T3 (da) | Pyrazinyl-piperazin-forbindelser, deres anvendelse og fremstilling | |
| PT1259489E (pt) | Compostos azapoliciclicos condensados con arilo. | |
| FI905839A0 (fi) | Menetelmä uusien terapeuttisesti käyttökelpoisten trisyklisten, typpipitoisten yhdisteiden valmistamiseksi | |
| ATE437872T1 (de) | Proteinkinaseinhibitoren | |
| EA200000592A1 (ru) | Азаполициклические соединения, конденсированные с арилом | |
| SE0104332D0 (sv) | Therapeutic agents | |
| GEP20104959B (en) | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | |
| WO2005092858A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist | |
| EA200100994A1 (ru) | 1-АМИНОТРИАЗОЛО[4,3-а]ХИНАЗОЛИН-5-ОНЫ И/ИЛИ -5-ТИОНЫ, ИНГИБИРУЮЩИЕ ФОСФОДИЭСТЕРАЗУ-IV | |
| DE69838662D1 (de) | Morphinanderivate und ihre medizinische Anwendung | |
| MY133445A (en) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivetives | |
| RU98112237A (ru) | Новые производные индол-2,3-дион-3-оксима | |
| DE60014404D1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| KR970003440A (ko) | 삼환 5,6-디하이드로-9H-피라졸로[3,4-c]-1,2,4-트리아졸로[4,3-α]피리딘 | |
| MY133474A (en) | Aryl fused azapolycyclic compounds | |
| ATE66913T1 (de) | Amidverbindungen, verfahren zu ihrer herstellung und zusammensetzung zur aktivierung gastromotorischer funktionen. | |
| KR910015580A (ko) | 신규 콜린에스테라제 억제제로서의 삼환-일환식 아민 | |
| SE9901884D0 (sv) | Novel compounds their use and preparation | |
| ES2111086T3 (es) | Compuestos triciclicos anfoteros como agentes antihistaminicos y antialergicos. | |
| WO2006134486A3 (en) | Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists | |
| MXPA06000892A (es) | Compuestos azapoliciclicos arilo fusionados. | |
| ATE398131T1 (de) | Kondensierte camptothecine als antitumormittel | |
| RU94016876A (ru) | Производные имидазо (5,1-с) (1,4) бензоксазин-1-она, способ их получения, фармацевтическая композиция и промежуточные соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: BIOVITRUM AB (PUBL) (SE) Free format text: ALTERADO DE: BIOVITRUM AB |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B15V | Prolongation of time limit allowed |
Free format text: RECONHECIDO OBSTACULO ADMINISTRATIVO E DEVOLVIDO 30 DIAS, NOS TERMOS DO ARTIGO 221 2O DA LPI E DA RESOLUCAO 116/2004. |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |